Patents by Inventor Michael W. Reed
Michael W. Reed has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20040191796Abstract: Oligonucleotide-fluorophore-quencher conjugates wherein the fluorophore moiety has emission wavelengths in the range of about (300) to about (800) nm, and or where the quencher includes a substituted 4-(phenyldiazenyl)phenylamine structure provide improved signal to noise ratios and other advantageous characteristics in hybridization and related assays. The oligonucleotide-fluorophore-quencher conjugates can be synthesized by utilizing novel phosphoramidite reagents that incorporate the quencher moiety based on the substituted 4-(phenyldiazenyl)phenylamine structure, and or novel phosphoramidite reagents that incorporate a fluorophore moiety based on the substituted coumarin, substituted 7-hydroxy-3H-phenoxazin-3-one, or substituted 5,10-dihydro-10 [phenyl]pyrido[2,3-d;6,5-d′]dipyrimidine-2,4,6,8-(1H, 3H, 7H, 9H, 10H)-tetrone structure.Type: ApplicationFiled: June 25, 2003Publication date: September 30, 2004Applicant: EPOCH PHARMACEUTICALS, INC.Inventors: Michael W. Reed, Eugeny Alexander Lukhtanov, Alexander A. Gall, Robert O. Dempcy
-
Publication number: 20040191824Abstract: The present invention provides a nucleoside comprising a pyrazolopyrimidine base and a process for producing the same. In particular, the processes of the present invention comprises using a halogenated pyrazolopyrimidine base and removing the halogen after the base is coupled to a sugar moiety. The presence of the halogen on the nucleoside base allows facile and economical production of a large quantity of nucleosides.Type: ApplicationFiled: April 1, 2004Publication date: September 30, 2004Applicant: Epoch Biosciences, Inc.Inventors: Robert O. Dempcy, A. David Adams, Michael W. Reed, Yevgeniy S. Belousov
-
Publication number: 20040081959Abstract: Oligonucleotide probes containing two labels are provided and are useful in hybridization assays. The probes can also contain a minor groove binding group.Type: ApplicationFiled: March 29, 2002Publication date: April 29, 2004Applicant: Epoch Biosciences, Inc.Inventors: Michael W. Reed, Eugeny Alexander Lukhtanov, Alexander A. Gall, Robert O. Dempcy, Nicolaas M.J. Vermeulen
-
Patent number: 6727356Abstract: Oligonucleotide-fluorophore-quencher conjugates wherein the fluorophore moiety has emission wavelengths in the range of about 300 to about 800 nm, and or where the quencher includes a substituted 4-(phenyldiazenyl)phenylamine structure provide improved signal to noise ratios and other advantageous characteristics in hybridization and related assays. The oligonucleotide-fluorophore-quencher conjugates can be synthesized by utilizing novel phosphoramidite reagents that incorporate the quencher moiety based on the substituted 4-(phenyldiazenyl)phenylamine structure, and or novel phosphoramidite reagents that incorporate a fluorophore moiety based on the substituted coumarin, substituted 7-hydroxy-3H-phenoxazin-3-one, or substituted 5,10-dihydro-10-[phenyl]pyrido[2,3-d;6,5-d′]dipyrimidine-2,4,6,8-(1H,3H,7H,9H,10H)-tetrone structure.Type: GrantFiled: December 8, 1999Date of Patent: April 27, 2004Assignee: Epoch Pharmaceuticals, Inc.Inventors: Michael W. Reed, Eugeny Alexander Lukhtanov, Alexander A. Gall, Robert O. Dempcy
-
Patent number: 6699975Abstract: Oligonucleotide-fluorophore-quencher conjugates wherein the fluorophore moiety has emission wavelengths in the range of about 300 to about 800 nm, and or where the quencher includes a substituted 4-(phenyldiazenyl)phenylamine structure provide improved signal to noise ratios and other advantageous characteristics in hybridization and related assays. The oligonucleotide-fluorophore-quencher conjugates can be synthesized by utilizing novel phosphoramidite reagents that incorporate the quencher moiety based on the substituted 4-(phenyidiazenyl)phenylamine structure, and or novel phosphoramidite reagents that incorporate a fluorophore moiety based on the substituted coumarin, substituted 7-hydroxy-3H-phenoxazin-3-one, or substituted 5,10-dihydro-10-[phenyl]pyrido[2,3-d;6,5-d′]dipyrimidine-2,4,6,8-(1H,3H,7H,9H,10H)-tetrone structure.Type: GrantFiled: March 7, 2002Date of Patent: March 2, 2004Assignee: Epoch Biosciences, Inc.Inventors: Michael W. Reed, Eugeny Alexander Lukhtanov, Alexander A. Gall, Robert O. Dempcy
-
Patent number: 6653473Abstract: Oligonucleotide probes containing two labels are provided and are useful in hybridization assays. The probes can also contain a minor groove binding group.Type: GrantFiled: February 26, 2002Date of Patent: November 25, 2003Assignee: Epoch Biosciences, Inc.Inventors: Michael W. Reed, Eugeny Alexander Lukhtanov, Alexander A. Gall, Robert O. Dempcy, Nicolaas M. J. Vermeulen
-
Publication number: 20030096254Abstract: Oligonucleotide probes containing two labels are provided and are useful in hybridization assays. The probes can also contain a minor groove binding group.Type: ApplicationFiled: March 29, 2002Publication date: May 22, 2003Applicant: Epoch Biosciences, Inc.Inventors: Michael W. Reed, Eugeny Alexander Lukhtanov, Alexander A. Gall, Robert O. Dempcy, Nicolaas M.J. Vermeulen
-
Publication number: 20030078413Abstract: The present invention provides a nucleoside comprising a pyrazolopyrimidine base and a process for producing the same. In particular, the processes of the present invention comprises using a halogenated pyrazolopyrimidine base and removing the halogen after the base is coupled to a sugar moiety. The presence of the halogen on the nucleoside base allows facile and economical production of a large quantity of nucleosides.Type: ApplicationFiled: September 12, 2001Publication date: April 24, 2003Applicant: Epoch Biosciences, Inc.Inventors: Robert O. Dempcy, A. David Adams, Michael W. Reed
-
Publication number: 20030008304Abstract: Oligonucleotide probes containing two labels are provided and are useful in hybridization assays. The probes can also contain a minor groove binding group.Type: ApplicationFiled: February 26, 2002Publication date: January 9, 2003Applicant: Epoch Biosciences, Inc.Inventors: Michael W. Reed, Eugeny Alexander Lukhtanov, Alexander A. Gall, Robert O. Dempcy, Nicolaas M.J. Vermeulen
-
Publication number: 20020155484Abstract: Oligonucleotide-fluorophore-quencher conjugates wherein the fluorophore moiety has emission wavelengths in the range of about 300 to about 800 nm, and or where the quencher includes a substituted 4-(phenyldiazenyl)phenylamine structure provide improved signal to noise ratios and other advantageous characteristics in hybridization and related assays. The oligonucleotide-fluorophore-quencher conjugates can be synthesized by utilizing novel phosphoramidite reagents that incorporate the quencher moiety based on the substituted 4-(phenyidiazenyl)phenylamine structure, and or novel phosphoramidite reagents that incorporate a fluorophore moiety based on the substituted coumarin, substituted 7-hydroxy-3H-phenoxazin-3-one, or substituted 5,10-dihydro-10-[phenyl]pyrido[2,3-d;6,5-d′]dipyrimidine-2,4,6,8-(1H,3H,7H,9H,10H)-tetrone structure.Type: ApplicationFiled: March 7, 2002Publication date: October 24, 2002Applicant: EPOCH PHARMACEUTICALS, INC.Inventors: Michael W. Reed, Eugeny Alexander Lukhtanov, Alexander A. Gall, Robert O. Dempcy
-
Publication number: 20020034754Abstract: Oligonucleotide probes containing two labels are provided and are useful in hybridization assays. The probes can also contain a minor groove binding group.Type: ApplicationFiled: June 6, 2001Publication date: March 21, 2002Inventors: Michael W. Reed, Eugeny Alexander Lukhtanov, Alexander A. Gall, Robert O. Dempcy, Nicolaas M.J. Vermeulen
-
Patent number: 6072046Abstract: Diaziridinyl-aryl and bis-[di(chloroethyl)amino]-aryl oligonucleotide conjugates have a sequence that is complementary in the triplex forming sense to a target sequence in duplex nucleic acid. The diaziridinyl-aryl and bis-[di(chloroethyl)amino]-aryl oligonucleotide conjugates effectively cross-link with both strands of the targeted duplex nucleic acid.Type: GrantFiled: August 26, 1998Date of Patent: June 6, 2000Assignee: Epoch Pharmaceuticals, Inc.Inventors: Michael W. Reed, Igor V. Kutyavin, Eugeny A. Lukhtanov, J. Ansel Wald, Rich B. Meyer, Jr.
-
Patent number: 5795560Abstract: Targeting protein-diagnostic/therapeutic agent conjugates joined by stabilized Schiff base linkages are disclosed. Schiff base linkage of targeting protein and agent is accomplished without exposure of the targeting protein to harsh oxidizing or reducing conditions. The cleavable, heterobifunctional linkers that are described provide certain advantages relating to in vivo administration of targeting protein conjugates, including controlled release of active agent at a target site.Type: GrantFiled: May 16, 1996Date of Patent: August 18, 1998Assignee: NeoRx CorporationInventor: Michael W. Reed
-
Patent number: 5746997Abstract: Halogenated oligonucleotides and particularly radiohalogenated oligonucleotides are prepared by reacting a modified oligonucleotide with a trialkylstannylaryl reagent, such as an active ester of 4-(tri-n-butyl)benzoic acid. The modified oligonucleotide has a reactive group, such as an NH.sub.2 group, covalently attached to a terminal phosphate or to a heterocyclic base, which reacts with the trialkylstannylaryl reagent to provide a trialkylstannylaryl-ODN conjugate. The trialkylstannyl group of the trialkylstannylaryl-ODN conjugate is rapidly replaced by halogen upon treatment with electrophilic halogen, such as I.sup.+, that is formed when a halogen salt is treated with an oxidizing agent. The trialkylstannylaryl-ODN conjugate is significantly more lipophilic than the halogenated ODN and is readily separated from the halogenated ODN by simple reverse phase column chromatography.Type: GrantFiled: October 2, 1996Date of Patent: May 5, 1998Assignee: Epoch Pharmaceuticals, Inc.Inventor: Michael W. Reed
-
Patent number: 5667976Abstract: Compositions and methods for covalently immobilizing an oligonucleotide onto a polymer-coated solid support or similar structure are provided. Specifically, the polymer-coated support, such as a bead, possesses a large number of activatable moieties, preferably primary and secondary amines. An oligonucleotide is activated with a monofunctional or multifunctional reagent, preferably the homotrifunctional reagent cyanuric chloride. The resultant covalently immobilized oligonucleotides on the support serve as nucleic acid probes, and hybridization assays can be conducted wherein specific target nucleic acids are detected in complex biological samples. The beads or similar structures can be employed free in solution, such as in a microtiter well format; in a flow-through format, such as in a column; or in a dipstick. Additionally, dichlorotriazine oligonucleotides and processes for activating oligonucleotides by treatment with cyanuric chloride and derivatives are included in the present invention.Type: GrantFiled: February 14, 1996Date of Patent: September 16, 1997Assignee: Becton Dickinson and CompanyInventors: Jeffrey Van Ness, Charles R. Petrie, John C. Tabone, Nicolaas M.J. Vermeulen, Michael W. Reed
-
Patent number: 5646126Abstract: Oligonucleotides having approximately 8 to 18 nucleotide units and a 3'-tail which includes asteroid structure attached to the 3'-end through the A ring of the steroid skeleton and which form substantially stable duplexes at physiological temperature, have selective cytotoxic activity against certain tumor cell lines.Type: GrantFiled: February 28, 1994Date of Patent: July 8, 1997Assignees: Epoch Pharmaceuticals, Yale UniversityInventors: Yung-chi Cheng, Eugeny A. Lukhtanov, Rich B. Meyer, Jr., Balakrishna S. Pai, Michael W. Reed, James H. Zhou
-
Patent number: 5633351Abstract: Targeting protein-diagnostic/therapeutic agent conjugates joined by stabilized Schiff base linkages are disclosed. Schiff base linkage of targeting protein and agent is accomplished without exposure of the targeting protein to harsh oxidizing or reducing conditions. The cleavable, heterobifunctional linkers that are described provide certain advantages relating to in vivo administration of targeting protein conjugates, including controlled release of active agent at a target site.Type: GrantFiled: November 1, 1994Date of Patent: May 27, 1997Assignee: NeoRx CorporationInventor: Michael W. Reed
-
Patent number: 5574142Abstract: A covalently linked conjugate of an oligonucleotide (ODN) with a peptide and a carrier or targeting ligand (ODN-peptide-carrier) includes a therapeutic oligonucleotide which is capable of selectively binding to a target sequence of DNA, RNA or protein inside a target cell. The ODN is covalently linked to a peptide which is capable of being cleaved by proteolytic enzymes inside the target cell. The peptide, in turn is covalently linked to a carrier or targeting ligand moiety which facilitates delivery of the entire ODN-peptide-carrier conjugate into the cell, and preferably into a specific target tissue type. Inside the cell, the peptide is cleaved, releasing the ODN which, by binding to the target DNA, RNA or protein sequence, brings about a beneficial result.Type: GrantFiled: December 15, 1992Date of Patent: November 12, 1996Assignee: MicroProbe CorporationInventors: Rich B. Meyer, Jr., Alexander A. Gall, Michael W. Reed
-
Patent number: 5512667Abstract: Oligonucleotides having a low molecular weight tail molecules joined to the 3' terminus of the oligonucleotide via a linking molecule of the structure:Z is ##STR1## wherein ##STR2## m and m' are positive integers less than 11, n is 0 or 1 and Q is a connecting group, are synthesized by selectively reacting three independent functional groups on the linking molecule, i.e., an amine, a primary hydroxyl and a secondary hydroxyl, in a stepwise manner. A tail molecule R is first connected to the amino functionality of the linking molecule. Next the linking molecule-tail molecule combination is attached to a solid state support via the secondary hydroxyl group. The oligonucleotide is systematically stepwise synthesized beginning on the primary hydroxyl group followed by release of the oligonucleotide having the low molecular weight tailed joined to its 3' terminus from the solid state support.Type: GrantFiled: February 3, 1993Date of Patent: April 30, 1996Inventors: Michael W. Reed, Rich B. Meyer, Jr.
-
Patent number: 5419966Abstract: A solid support for oligonucleotide synthesis has the structure ##STR1## where CPG represents a controlled pore glass matrix, the wavy line represents a carbon chain covalently linking the NH group with the controlled pore glass matrix, X is 2,2'-dimethoxytrityl or H, and R is alkyl, aryl, arylalkyl, heteroalkyl, or heteroaryl. The dimethoxytrityl group is removed from the solid support by treatment with acid, and the oligonucleotide is built, step-by-step in a conventional synthesizer after attachment of the 3' end of the first oligonucleotide unit to the hydroxyl function connected to the R group.Type: GrantFiled: July 12, 1993Date of Patent: May 30, 1995Assignee: MicroProbe CorporationInventors: Michael W. Reed, Rich B. Meyer, Jr., Charles R. Petrie, John C. Tabone